---
layout: default
title: Silver
parent: Model Prediction Only (L5)
nav_order: 1162
evidence_level: L5
indication_count: 1
monitor_inn: "SILVER"
predicted_indications: ["bone Paget disease"]
last_modified_at: 2026-10-14
description: "Silver: predicted new indication Bone Paget disease (evidence level L5). Approved use: Not available"
---

# Silver
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **1** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist" markdown="1">

## Pharmacist Assessment Report

</div>

# SILVER: From an Unspecified Original Indication to Bone Paget Disease

## One-Sentence Summary

Silver (colloidal silver) has no original approved indication on record in the data compiled for this report, and its only US license is cancelled.
The TxGNN model predicts it may be effective for **bone Paget disease**, but there are **0 clinical trials** and no relevant therapeutic publications supporting this prediction.
The 5 retrieved papers use silver only as a staining reagent or concern unrelated topics, so the prediction is most likely a literature co-occurrence artifact.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available (the only license lists no approved indication) |
| Predicted New Indication | Bone Paget disease |
| TxGNN Prediction Score | 99.67% |
| Evidence Level | L5 |
| US Market Status | Cancelled only |
| Number of NDAs | 1 (cancelled) |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. No original indication is recorded either, so the relationship between an existing use and Paget disease of bone cannot be established.

The retrieved literature does not describe silver as a treatment. Silver appears only as a histological tool: silver staining of nucleolar organizer regions in osteoclast nuclei, silver impregnation of bone sections, and osteoid quantification. The Paget disease papers concern osteoclast features (such as increased nucleolar organizer regions and Gallium-67 citrate uptake), not a therapeutic effect of silver.

The high TxGNN score (99.67%) therefore does not have a supporting pharmacological rationale in the available data. The link appears to come from the co-occurrence of "silver" and "Paget's bone disease" in the literature rather than from a real drug-disease relationship.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [9836854](https://pubmed.ncbi.nlm.nih.gov/9836854/) | 1998 | Basic/histopathology study | Bone | Silver-stained nucleolar organizer regions (AgNORs) are increased in osteoclast nuclei in Paget's disease; silver is used as a stain, not a treatment |
| [3163726](https://pubmed.ncbi.nlm.nih.gov/3163726/) | 1988 | Imaging/localization study | J Nucl Med | Gallium-67 citrate localizes in osteoclast nuclei in Paget's disease; involves gallium, not silver |
| [9227338](https://pubmed.ncbi.nlm.nih.gov/9227338/) | 1997 | Methods/basic study | J Pathol | Quantification of vitamin D receptor mRNA by in situ RT-PCR; not related to silver therapy |
| [2420233](https://pubmed.ncbi.nlm.nih.gov/2420233/) | 1985 | Histological methods | Anat Anz | Silver impregnation technique for bone tissue sections |
| [4111887](https://pubmed.ncbi.nlm.nih.gov/4111887/) | 1972 | Histological methods | Stain Technol | Silver staining of bone before decalcification to quantify osteoid |

None of these papers evaluates silver as a therapy for Paget disease of bone.

## US Market Information

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| Not available | Colloidal Silver (BioActive Nutritional, Inc.) | Liquid | Not listed (status: cancelled) |

Other silver dosage forms appear in the records (pellet, gel, spray, ointment), but no active license exists for any of them.

## Safety Considerations

Please refer to the package insert for safety information. No warnings, contraindications, or drug interaction data were found for this drug in the data compiled for this report.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction rests on a model score alone (Evidence Level L5). There are no clinical trials, no mechanistic data, and the literature uses silver only as a staining reagent. The only US license is cancelled, and no safety information could be retrieved.

**To proceed, the following is needed:**
- FDA package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data (for example, from DrugBank)
- Evidence of a genuine pharmacological or clinical link between silver and Paget disease of bone, beyond histological staining
- Review of whether the prediction is a literature-mining artifact
- Assessment of route compatibility and a safety assessment of systemic silver exposure
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

